Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

F. Sclafani1, I. Chau1, D. Cunningham1, C. Peckitt1, A. Lampis2, J.C. Hahne2, C. Braconi1,3, J. Tabernero4, B. Glimelius5, A. Cervantes6, R. Begum1, D. Gonzalez De Castro1, S. Hulkkki Wilson1, Z. Etahir1, A. Wotherspoon1, D. Tait1, G. Brown1, J. Oates1 & N. Valeri1,2*

1Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey; 2Division of Molecular Pathology, The Institute of Cancer Research, London and Sutton; 3Division of Cancer Therapeutics, The Institute of Cancer Research, London and Sutton, UK; 4Department of Medical Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain; 5Department of Immunology, Genetics and Pathology, University of Uppsala, Uppsala, Sweden; 6Department of Hematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

Received 23 April 2015; revised 29 May 2015; accepted 26 June 2015

Background: Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.

Patients and methods: We analysed rs61764370 in EXPERT-C, a randomised phase II trial of neoadjuvant CAPOX followed by chemoradiotherapy, surgery and adjuvant CAPOX plus or minus cetuximab in locally advanced rectal cancer. DNA was isolated from formalin-fixed paraffin-embedded tumour tissue and genotyped using a PCR-based commercially available assay. Kaplan–Meier method and Cox regression analysis were used to calculate survival estimates and compare treatment arms.

Results: A total of 155/164 (94.5%) patients were successfully analysed, of whom 123 (79.4%) and 32 (20.6%) had the LCS-6 TT and LCS-6 TG genotype, respectively. Carriers of the G allele were found to have a statistically significantly higher rate of complete response (CR) after neoadjuvant therapy (28.1% versus 10.6%; P = 0.020) and a trend for better 5-year progression-free survival (PFS) (77.4% versus 64.5%; hazard ratio (HR) 0.56; P = 0.152) and overall survival (OS) rates (80.3% versus 71.9%; HR 0.59; P = 0.234). Both CR and survival outcomes were independent of the use of cetuximab. The negative prognostic effect associated with KRAS mutation appeared to be stronger in patients with the LCS-6 TT genotype (HR PFS 1.70, P = 0.078; HR OS 1.79, P = 0.082) compared with those with the LCS-6 TG genotype (HR PFS 1.33, P = 0.713; HR OS 1.01, P = 0.995).

Conclusion: This analysis suggests that rs61764370 may be a biomarker of response to neoadjuvant treatment and an indicator of favourable outcome in locally advanced rectal cancer possibly by mitigating the poor prognosis of KRAS mutation. In this setting, however, this polymorphism does not appear to predict cetuximab benefit.

Key words: LCS-6 KRAS variant, single-nucleotide polymorphism, let-7, KRAS, cetuximab, rectal cancer

introduction

miRNAs are short, non-coding, sequences of nucleotides which regulate gene expression by binding to complementary sites in the 3′-untranslated region (3′UTRs) of target miRNAs [1]. Approximately 2000 miRNAs have been described in humans so far and mounting evidence suggests that these molecules may play an important role in the mechanisms of cell proliferation, differentiation, carcinogenesis, tumour progression and response to treatment [1–4]. The lethal-7 (let-7) family members are among the most studied miRNAs in human malignancies. They generally act as tumour suppressors by down-regulating oncogenes involved in the control of the cell cycle or intracellular signalling cascades [5]. KRAS is an established target of let-7, several complementary sites for this miRNA being described in the 3′UTR of the mRNA [6]. A single-nucleotide polymorphism (SNP) (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) has been reported in ~18% of Caucasians with colorectal cancer (CRC) [7]. This polymorphism modifies the let-7 binding affinity.
for KRAS ultimately leading to reduced KRAS inhibition and increased tumour proliferation [8].

A number of studies investigated the role of the LCS-6 variant either as a prognostic marker in early CRC or as a predictive marker for anti-epidermal growth factor receptor (EGFR) therapies in metastatic CRC [7, 9–16]. The results have been largely inconsistent possibly due to a significant inter-study heterogeneity with regard to sample size, patient characteristics and treatment. Notably, although the prognostic relevance of KRAS mutation appears greater in rectal cancer compared with colon cancer [17, 18], studies addressing the role of this polymorphism in a homogeneous series of rectal cancer patients are lacking.

We analysed the LCS-6 variant in EXPERT-C, an international, multicentre, randomised phase II trial investigating the addition of cetuximab to a sequential treatment with neoadjuvant capcitabine and oxaliplatin (CAPOX) followed by chemo-radiotherapy (CRT), surgery and adjuvant CAPOX in patients with locally advanced rectal cancer (LARC) [19].

**methods**

The EXPERT-C trial included LARC patients with at least one of the following magnetic resonance imaging high-risk features: tumour within 1 mm of mesorectal fascia, T3 distal (at/below levators) tumour, T3c/T3d tumour (extramural extension ≥5 mm), T4 tumour, extramural vascular invasion [19]. Patients were randomised to four cycles of neoadjuvant CAPOX followed by capcitabine-based CRT, surgery and four cycles of adjuvant CAPOX or the same treatment plus cetuximab (Figure 1) [19]. All patients provided written informed consent.

**molecular analysis**

DNA was isolated from formalin-fixed paraffin-embedded tumour tissue from pre-treatment biopsies and/or resection samples using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany). Samples were genotyped using custom Taqman assay (Life Technologies, Carlsbad, CA) (probes available upon request). Cases, negative controls and duplicate samples were processed in a random order. Both inter- and intra-plate duplicates (10% of the samples) were 100% concordant. Analysis of KRAS (exons 2–4), NRAS (exons 2–4) and BRAF (codon 600) was carried out as previously described [19, 20].

**statistical considerations**

The primary end point of the EXPERT-C trial was complete response (CR) in patients with KRAS/BRAF wild-type tumours. Hardy–Weinberg equilibrium was assessed using the $\chi^2$ test. The Kaplan–Meier method was used to calculate survival estimates and comparison between the treatment arms was carried out using a log-rank analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were obtained from Cox regression. An interaction term between treatment arm and LCS-6 genotype was included in the Cox regression. Multivariate Cox regression was used to assess whether a significant interaction remained significant after addition of prognostic variables. Variables were included in the multivariate model using forward selection if $P$ value $<0.1$.

**results**

One hundred and sixty-four patients were enrolled into the EXPERT-C trial. Of these, 155 (94.5%) had tumour tissue available for LCS-6 genotyping, 77 in the CAPOX-C arm and 78 in the CAPOX arm. Table 1 shows patient characteristics. No significant differences, overall and by treatment arm, were observed compared with the original EXPERT-C trial population (data not shown).

Genotyping was successful in all assessable patients. One hundred and twenty-three patients (79.4%) had the LCS-6 TT genotype (CAPOX = 65; CAPOX-C = 58) while 32 (20.6%) had the LCS-6 TG genotype (CAPOX = 13; CAPOX-C = 19). Hardy–Weinberg equilibrium was observed ($P = 0.152$). There was no association between the LCS-6 genotype and baseline characteristics including demographics and clinico-pathological features. More patients in the LCS-6 variant group had tumours harbouring KRAS (54.8% versus 41.5%), KRAS/NRAS (58.1% versus 45.8%) and BRAF mutation (6.5% versus 1.7%). These differences however were not statistically significant.

After neoadjuvant treatment, 13/123 patients (10.6%) in the LCS-6 TT genotype group achieved CR compared with 9/32

---

**Table 1. Baseline patient characteristics by LCS6 genotype**

<table>
<thead>
<tr>
<th>LCS6 TT genotype</th>
<th>LCS6 TG genotype</th>
<th>$P$ value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>(N=123)</strong></td>
<td><strong>(N=32)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>n</strong></td>
<td><strong>%</strong></td>
<td><strong>n</strong></td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>75</td>
<td>61.0</td>
</tr>
<tr>
<td>Female</td>
<td>48</td>
<td>39.0</td>
</tr>
<tr>
<td><strong>Age [mean (SD) and range]</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 (10.5)</td>
<td>38–74</td>
<td>61 (11.1)</td>
</tr>
<tr>
<td><strong>WHO performance status</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>57</td>
<td>46.3</td>
</tr>
<tr>
<td>≥1</td>
<td>66</td>
<td>53.7</td>
</tr>
<tr>
<td><strong>MRI-defined high-risk features</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3c–T3d</td>
<td>81</td>
<td>65.9</td>
</tr>
<tr>
<td>T4</td>
<td>29</td>
<td>23.6</td>
</tr>
<tr>
<td>CRM involved/at risk</td>
<td>73</td>
<td>59.3</td>
</tr>
<tr>
<td>EMVI positive</td>
<td>90</td>
<td>73.2</td>
</tr>
<tr>
<td>Low-lying tumour</td>
<td>87</td>
<td>70.7</td>
</tr>
<tr>
<td><strong>Mutations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRAS</td>
<td>49</td>
<td>41.5</td>
</tr>
<tr>
<td>NRAS</td>
<td>5</td>
<td>4.3</td>
</tr>
<tr>
<td>KRAS/NRAS</td>
<td>54</td>
<td>45.8</td>
</tr>
<tr>
<td>BRAF</td>
<td>2</td>
<td>1.7</td>
</tr>
<tr>
<td>PIK3CA</td>
<td>8</td>
<td>6.8</td>
</tr>
<tr>
<td>TP53</td>
<td>69</td>
<td>52.6</td>
</tr>
</tbody>
</table>

**SD, standard deviation; WHO, World Health Organisation; MRI, magnetic resonance imaging; CRM, circumferential resection margin; EMVI, extramural venous invasion.**

---

**Figure 1.** EXPERT-C trial design. R, randomisation; CAPOX, capcitabine and oxaliplatin; C, cetuximab; Cape, capcitabine; RT, radiotherapy.
(28.1%) in the LCS-6 TG genotype group \( (P = 0.020, \text{adjusted } P = 0.044) \). In both groups, no significant differences in CR rate were observed with or without cetuximab (10.3% versus 10.8%, \( P = 1.00 \) and 31.6% versus 23.1%, \( P = 0.704 \), respectively, treatment*LCS-6 \( P \) interaction = 0.638) or in KRAS wild-type versus KRAS mutant tumours (10.1% versus 8.2%, \( P = 1.00 \) and 21.4% and 29.4%, \( P = 0.698 \), KRAS*LCS-6 \( P \) interaction = 0.534).

After a median follow-up of 64.9 months (95% CI 62.8–67.2), numerically higher 5-year progression-free survival (PFS) [77.4% versus 64.5%, HR 0.56 (95% CI 0.25–1.24), \( P = 0.152 \)] and 5-year overall survival (OS) rates [80.3% versus 71.9%, HR 0.59 (95% CI 0.25–1.41), \( P = 0.234 \)] favouring the LCS-6 TG genotype group were observed in the entire population (Figure 2). In cetuximab-treated patients, survival outcomes were independent of the genotype type group. The 5-year PFS and OS rates in patients with the same genotype treated in the CAPOX arm \( [5\text{-year PFS } 78.6\% \text{ versus } 69.0\%, \text{HR } 0.59 (95\% \text{ CI } 0.17–1.43), \text{HR OS } 0.62 (95\% \text{ CI } 0.32–1.21), \text{HR OS } 0.159] \) were 66.7% and 77.0%, respectively, compared with 62.7% and 67.4% in the CAPOX-C arm; 78.9% and 83.9%, respectively, compared with 75.0% and 75.0% in patients with the same genotype treated in the LCS-6 TG genotype group had tumour recurrence. The most common sites of disease recurrence were liver (41.7%), lung (44.4%), peritoneum (19.4%) and lymph nodes (16.7%). The rate of liver relapse was different between the two groups: 15 patients out of 123 (12.2%) in the LCS-6 TT genotype group were diagnosed with liver metastases (accounting for 48.4% of all relapsed patients in this group) compared with 0/32 patients with the LCS-6 TG genotype \( (P = 0.038) \).

When the survival outcomes were analysed by KRAS status, the prognostic trend associated with the LCS-6 TT genotype appeared to be stronger in patients with KRAS mutant tumours \([5\text{-year PFS } 75.0\% \text{ versus } 54.5\%, \text{HR } 0.49 (95\% \text{ CI } 0.17–1.43), \text{HR OS } 0.42 (95\% \text{ CI } 0.12–1.41), \text{HR OS } 0.158] \), compared with patients with KRAS wild-type tumours \([5\text{-year PFS } 78.6\% \text{ versus } 69.0\%, \text{HR } 0.59 (95\% \text{ CI } 0.17–1.96), \text{HR OS } 0.385; 5\text{-year OS } 78.6\% \text{ versus } 76.5\%, \text{HR } 0.78 (95\% \text{ CI } 0.23–2.69), \text{HR OS } 0.703] \) (Figure 4). KRAS mutation was found to have a negative prognostic impact in patients with the KRAS wild-type group.

**Figure 2.** Progression-free survival (A) and overall survival (B) by LCS6 genotype in the entire study population. HR, hazard ratio; CI, confidence interval.

**Figure 3.** Progression-free survival (A) and overall survival (B) by LCS6 genotype and treatment arm. a, patients with LCS6 TT genotype treated in the CAPOX arm; b, patients with LCS6 TT genotype treated in the CAPOX-C arm; c, patients with LCS6 TG genotype treated in the CAPOX arm; d, patients with LCS6 TG genotype treated in the CAPOX-C arm. HR, hazard ratio; CI, confidence interval.
LCS-6 TT genotype [HR PFS: 1.70 (95% CI 0.94–3.08), \(P = 0.078\); HR OS: 1.79 (95% CI 0.93–3.44), \(P = 0.082\)] but not in those with the LCS-6 TG genotype [HR PFS: 1.33 (95% CI 0.30–5.92), \(P = 0.713\); HR OS: 1.01 (95% CI 0.20–4.99), \(P = 0.995\)]. However, possibly due to the small numbers, the interaction test did not show any interaction between the LCS-6 genotype and KRAS mutational status. a, patients with LCS6 TT genotype and KRAS wild-type tumour; b, patients with LCS6 TT genotype and KRAS mutant tumour; c, patients with LCS6 TG genotype and KRAS wild-type tumour; d, patients with LCS6 TG genotype and KRAS mutant tumour. HR, hazard ratio; CI, confidence interval.

**discussion**

In this retrospective analysis of the EXPERT-C trial, we showed that rs61764370 was not a predictive factor for cetuximab in LARC. However, this polymorphic variant was associated with a higher rate of CR to neoadjuvant therapy and a trend towards better survival outcomes, especially in the subgroup of patients with KRAS mutant tumours.

To our knowledge, this is the first report on the role of the LCS-6 variant in a homogeneous series of LARC. Previous studies investigating this SNP were either restricted to patients with colon cancer or conducted in unselected CRC populations [7, 9–16]. However, differences exist between colon and rectal cancers with regards to tumour biology and treatment approach including frequency of microsatellite instability and BRAF mutation, prognostic relevance of KRAS mutation, miRNA expression profile and routine use of radiotherapy in LARC [21].

We assessed the role of the LCS-6 variant with an aim to validate two intriguing hypotheses generated by previous analyses. The first hypothesis is that this variant may predict benefit from anti-EGFR agents and refine the selection of metastatic CRC patients who are candidate for these therapies [16]. The second hypothesis is that the LCS-6 G allele may be a favourable prognostic factor in the non-metastatic setting and be used in the decision-making process regarding adjuvant treatment [14]. To this end, we used a prospective series of LARC patients who were treated with systemic chemotherapy followed by CRT plus or minus cetuximab in a randomised phase II trial [19].

The incidence of the LCS-6 variant in our population was in line with what has been previously reported [7, 16]. We could not find an association between this polymorphism and patient characteristics. Of note, our study is the first to include data on RAS (KRAS and NRAS, exon 2–4) mutation in this setting and, although a higher incidence of RAS and BRAF mutation was observed in carriers of the G allele, this was not statistically significant.

The main and novel finding of our analysis is that patients with the LCS-6 TG genotype had a higher rate of CR after preoperative treatment. This translated into numerically higher, but not statistically significantly improved, survival outcomes possibly due to the relatively small sample size, the low number of events and the limited statistical power of the study. Of note, the better prognosis of the LCS-6 variant group was independent of chemotherapy (as measured by KRAS expression) were different among cytotoxic agents [16].

**Figure 4.** Progression-free survival (A) and overall survival (B) by LCS6 genotype and KRAS mutational status. a, patients with LCS6 TT genotype and KRAS wild-type tumour; b, patients with LCS6 TT genotype and KRAS mutant tumour; c, patients with LCS6 TG genotype and KRAS wild-type tumour; d, patients with LCS6 TG genotype and KRAS mutant tumour. HR, hazard ratio; CI, confidence interval.
is consistent with previous reports. In early-stage CRC patients, Smits et al. showed that G carriers with stage I–II tumours harbouring KRAS mutation had a better cancer-specific survival compared with KRAS mutant patients with the LCS-6 TT genotype [14]. In contrast, patients with KRAS wild-type tumours had intermediate prognosis regardless of the LCS-6 genotype. An association between LCS-6 G allele and better prognosis was also reported in a series of stage III–IV CRC patients enriched with KRAS mutation [15]. Finally, in a recent analysis of the NCCTG N0147 trial, the outcome of G carriers with KRAS mutant stage III colon cancer appeared to be more similar to that of patients with KRAS wild-type tumours than that of patients with LCS-6 TT genotype and KRAS mutant tumour [16]. Altogether, these data seem to indicate that the LCS-6 variant may mitigate the unfavourable prognosis associated with KRAS mutation in the non-metastatic setting [17, 18]. It has been proposed that this effect may be secondary to induction of cellular senescence through overexpression of KRAS and increased signalling through the MAP-K cascade [14]. However, there are currently no data to confirm this hypothesis and the broad spectrum of cancer-related genes which are regulated by let-7 suggests that other mechanisms may be involved.

We recognise the limitations of our study including the retrospective design, the small numbers and the analysis of patients who were treated with investigational therapeutic strategies that do not reflect the current standard of care in this setting. Moreover, robust biological hypotheses to explain the study results are lacking. However, this analysis explores for the first time the predictive and prognostic role of the LCS-6 variant in LARC and provides another piece of the puzzle on the relationship between this SNP and anti-EGFR agents.

The management of LARC is orphan of established biomarkers that could lead to optimisation of patient selection, implementation of molecularly selected treatment approaches and improved outcomes. So far, studies investigating putative biomarkers in this setting have been largely unsuccessful. As a result, conventional clinico-pathological prognostic factors still remain the only available tools for individual patient risk assessment and treatment decision. Although genetic variations associated with SNPs have been reported to influence cancer risk, response to treatment and tumour prognosis in a number of tumour types including CRC, their value in routine practice is yet to be demonstrated.

Our analysis suggests that, in a Caucasian population, the rs61764370 SNP may influence the prognostic relevance of KRAS mutation which has been increasingly reported as a marker of response to treatment and tumour prognosis in a number of cancer-related genes which are regulated by let-7 suggests that other mechanisms may be involved.

We acknowledge support from the NIHR BRC at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research and from the Peter Stebbings Memorial Charity. We thank Brid M. Ryan (Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, USA) for technical advice on probe design. The EXPERT-C trial was supported by the NIHR BRC at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, the Peter Stebbings Memorial Charity, and the Pelican Cancer Foundation and by a grant from Merck & Co. Merck & Co. provided cetuximab, and Sanofi-Aventis provided oxaliplatin; neither company was involved in study design, data analysis, or manuscript preparation or had access to study data. The EXPERT-C trial was endorsed by Cancer Research UK.

funding

The work was supported by Cancer Research UK (CEA A18052), European Union FP7 (CIG 334261) and the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research (grant A62) to NV.

disclosure

DC received research funding from: Roche, Amgen, Celgene, Sanofi, Merck-Serono, Novartis, AstraZeneca, Bayer, Merrimack and MedImmune. CP has had advisory roles with Sanofi, JT has had advisory roles with Amgen, Roche, Sanofi-Aventis and Merck. AC has had advisory roles with Merck-Serono and Roche. He has received research funding from Roche and honoraria from Roche and Merck-Serono. IC has had advisory roles with Merck-Serono, Roche, Sanofi Oncology, Bristol Myers Squibb, Eli-Lilly, Novartis, Gilead Science. He has received research funding from Merck-Serono, Novartis, Roche and Sanofi Oncology, and honoraria from Roche, Sanofi Oncology, Eli-Lilly, Taiho. All other authors declare that they have no conflicts of interest.

references

Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study


1Department of Medical Oncology, Centre Antoine Lacassagne, Nice; 2Gustave Roussy, UMR 8126/CNRS, Villejuif; 3Department of Medical Oncology, University of Lyon, Centre Léon Bérard, and Hospices Civils de Lyon, Lyon; 4Department of Medical Oncology, Centre Jean Perin, Clermont-Ferrand; 5Department of Medical Oncology, Hôpital Bretagne Sud, Lorient, France; 6Department of Medical Oncology, CHU Dinant Godinne UCL, Namur, Belgium; 7Department of Medical Oncology, Centre Henri Becquerel, Rouen, France; 8Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires St-Luc and Institut de Recherche Clinique et Expérimentale (Pôle Miro), Université Catholique de Louvain, Brussels, Belgium; 9Department of Medical Oncology, Centre Georges François Leclerc, Dijon; 10Department of Medical Oncology, CHRJ de Tours, Tours; 11Department of Medical Oncology, Institut Curie-Hôpital René Huguenin, Saint-Cloud, France; 12Department of Medical Oncology, Clinique Sainte-Elisabeth, Namur, Belgium; 13Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France; 14GORTEC, Lausanne, Switzerland

Received 10 April 2015; revised 29 May 2015; accepted 2 June 2015

Background: Cetuximab in combination with platinum and 5-fluorouracil is the standard of care in the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab and taxane combinations have shown promising activity. This study evaluated the efficacy and safety of four cycles of docetaxel associated with cisplatin and cetuximab (TPEx), followed by maintenance with cetuximab every 2 weeks.

*Correspondence to: Prof. Joël Guigay, Department of Medical Oncology, Centre Antoine Lacassagne, 33 avenue de Valombreuse, 06189 Nice cedex 2, France. Tel: +33-4-92-03-15-01; E-mail: joel.guigay@nice.unican.fr

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.